Want to see HK:0570 full AI Analyst Report?
China Traditional Chinese Medicine Holdings Co (0570) AI Stock Analysis
Top Page
China Traditional Chinese Medicine Holdings Co
(HKEX:0570)
The score is held back primarily by deteriorating fundamentals (profitability falling to a 2025 net loss and softer revenue trends), despite support from a conservative balance sheet and strong recent operating/free cash flow. Technicals remain weak on a longer-term basis (price below 100/200-day averages with slightly negative MACD), while valuation is helped by the very high dividend yield but constrained by negative earnings (negative P/E).
China Traditional Chinese Medicine Holdings Co (0570) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 821.34M
- Dividend Yield
- 0.30%
- Average Volume (3M)
- 9.51M
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 0.45
- Revenue Growth
- -15.80%
- EPS Growth
- -298.94%
- Country
- Hong Kong
- Employees
- 14,846
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
China Traditional Chinese Medicine Holdings Co Business Overview & Revenue Model
Company Description
China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic...
How the Company Makes Money
The company primarily makes money by selling TCM products through a combination of wholesale/distribution channels and direct sales to healthcare providers and consumers, depending on the product and market. Key revenue streams typically include: (1)...
China Traditional Chinese Medicine Holdings Co Financial Statement Overview
Summary
Income statement weakness drives the score: profitability deteriorated from profits (2020–2023) to near break-even in 2024 and a net loss in 2025, alongside inconsistent revenue with declines in 2024 and ~8% further drop in 2025. Offsetting factors are a relatively conservative, low-leverage balance sheet and strong positive operating/free cash flow in 2024–2025, though cash flow has been volatile historically and durability should be monitored given the 2025 loss.
Income Statement
38NegativeBalance Sheet
74PositiveCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.64B | 14.74B | 16.51B | 18.12B | 14.30B | 19.05B |
| Gross Profit | 6.00B | 7.09B | 7.86B | 9.27B | 7.20B | 11.83B |
| EBITDA | 1.21B | 1.61B | 1.88B | 2.56B | 2.16B | 3.59B |
| Net Income | -999.73M | -342.07M | 54.07M | 1.29B | 764.49M | 1.93B |
Balance Sheet | ||||||
| Total Assets | 29.86B | 32.36B | 35.06B | 37.07B | 35.62B | 36.39B |
| Cash, Cash Equivalents and Short-Term Investments | 4.56B | 5.16B | 5.34B | 3.69B | 3.46B | 4.14B |
| Total Debt | 1.34B | 2.49B | 4.02B | 5.16B | 5.04B | 5.06B |
| Total Liabilities | 7.67B | 8.94B | 11.13B | 13.13B | 12.67B | 13.73B |
| Stockholders Equity | 19.69B | 20.48B | 21.20B | 21.16B | 20.17B | 19.72B |
Cash Flow | ||||||
| Free Cash Flow | 1.45B | 1.96B | 2.07B | 680.20M | 565.09M | -81.17M |
| Operating Cash Flow | 1.71B | 2.28B | 2.58B | 1.17B | 1.09B | 796.03M |
| Investing Cash Flow | -201.26M | -172.80M | -379.24M | -477.62M | -374.15M | -536.94M |
| Financing Cash Flow | -2.66B | -2.04B | -1.39B | -584.31M | -557.28M | -724.32M |
China Traditional Chinese Medicine Holdings Co Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0570, the sentiment is Negative. The current price of 1.17 is below the 20-day moving average (MA) of 1.19, below the 50-day MA of 1.26, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 42.13 is Neutral, neither overbought nor oversold. The STOCH value of 46.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0570.
China Traditional Chinese Medicine Holdings Co Peers Comparison
Overall Rating
HK:689665Neutral
HK:051259Neutral
HK:089758.6Neutral
HK:087457Neutral
HK:071954Neutral- HK:057053Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6896 | 65Neutral | HKD 1.44B | 5.82 | 16.70% | 17.44% | -5.37% | -18.03% |
| HK:0512 | 59Neutral | HKD 15.30B | 13.45 | 6.61% | 3.92% | 7.35% | -45.49% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0874 | 57Neutral | HKD 35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% |
| HK:0719 | 54Neutral | HKD 8.28B | 37.23 | 4.32% | 3.22% | -0.52% | -37.60% |
| HK:0570 | 53Neutral | HKD 5.89B | -4.81 | -4.98% | 0.30% | -15.80% | -298.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.17 | -1.16 | -49.79% | |
| HK:0874 | Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H | 12.86 | -5.10 | -28.41% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0512 | Grand Pharmaceutical Group Limited | 4.31 | -4.18 | -49.26% | |
| HK:6896 | Golden Throat Holdings Group Co Ltd | 1.95 | -1.15 | -37.14% | |
| HK:0719 | Shandong Xinhua Pharmaceutical Company Limited Class H | 5.35 | -1.42 | -20.94% |
China Traditional Chinese Medicine Holdings Co Corporate Events
China TCM Group Launches Connected Facility Upgrades in Mainland China
China Traditional Chinese Medicine Holdings Co. Limited has disclosed new connected transactions involving facility upgrades at two key subsidiaries in mainland China. The initiatives focus on renovating Shandong Yifang’s traditional Chinese me...
China TCM Gains NMPA Approval for Innovative Depression Treatment
China Traditional Chinese Medicine Holdings Co. Limited, a Hong Kong-based pharmaceutical group specializing in traditional Chinese medicine, is expanding its portfolio of Chinese patent medicines through innovative products developed by its Sinophar...
China TCM Sets Board Meeting to Approve 2026 Interim Results
China Traditional Chinese Medicine Holdings Co. Limited has scheduled a board meeting for 28 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The company also plans to arrange for the publication...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026